Jiaan Hu
About
In The Last Decade
Jiaan Hu
16 papers receiving 267 citations
Peers
Comparison fields: 5 of 61
- Physiology 116
- Molecular Biology 66
- Pulmonary and Respiratory Medicine 56
- Oncology 47
- Geriatrics and Gerontology 39
Countries citing papers authored by Jiaan Hu
This map shows the geographic impact of Jiaan Hu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jiaan Hu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jiaan Hu more than expected).
Fields of papers citing papers by Jiaan Hu
This network shows the impact of papers produced by Jiaan Hu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jiaan Hu. The network helps show where Jiaan Hu may publish in the future.
Co-authorship network of co-authors of Jiaan Hu
This figure shows the co-authorship network connecting the top 25 collaborators of Jiaan Hu. A scholar is included among the top collaborators of Jiaan Hu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jiaan Hu. Jiaan Hu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 1 | |
| 2 | 2 | |
| 3 | 3 | |
| 4 | 0 | |
| 5 | 38 | |
| 6 | 86 | |
| 7 | 0 | |
| 8 | A detrimental mutation on USP40 unlocks the tumorigenesis in a rare case of lung cancer. | 3 |
| 9 | 0 | |
| 10 | 16 | |
| 11 | 11 | |
| 12 | 17 | |
| 13 | 4 | |
| 14 | 5 | |
| 15 | 34 | |
| 16 | 5 | |
| 17 | 15 | |
| 18 | Gefitinib, an EGFR tyrosine kinase inhibitor, activates autophagy through AMPK in human lung cancer cells. | 14 |
| 19 | RAF1-MEK1-ERK/AKT axis may confer NSCLC cell lines resistance to erlotinib. | 19 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.